UBS Group’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21M | Buy |
1,870,522
+1,738,749
| +1,320% | +$19.5M | ﹤0.01% | 1812 |
|
|
2025
Q1 | $602K | Sell |
131,773
-8,016
| -6% | -$36.6K | ﹤0.01% | 4555 |
|
|
2024
Q4 | $788K | Sell |
139,789
-24,338
| -15% | -$137K | ﹤0.01% | 4385 |
|
|
2024
Q3 | $794K | Buy |
164,127
+57,425
| +54% | +$278K | ﹤0.01% | 3769 |
|
|
2024
Q2 | $521K | Sell |
106,702
-185,282
| -63% | -$904K | ﹤0.01% | 3895 |
|
|
2024
Q1 | $3.88M | Buy |
291,984
+88,633
| +44% | +$1.18M | ﹤0.01% | 2415 |
|
|
2023
Q4 | $2.83M | Buy |
203,351
+120,088
| +144% | +$1.67M | ﹤0.01% | 2536 |
|
|
2023
Q3 | $1.1M | Sell |
83,263
-4,811
| -5% | -$63.8K | ﹤0.01% | 2998 |
|
|
2023
Q2 | $1.65M | Sell |
88,074
-2,761
| -3% | -$51.8K | ﹤0.01% | 2843 |
|
|
2023
Q1 | $1.31M | Sell |
90,835
-152,939
| -63% | -$2.21M | ﹤0.01% | 2960 |
|
|
2022
Q4 | $4.72M | Buy |
243,774
+210,071
| +623% | +$4.06M | ﹤0.01% | 1880 |
|
|
2022
Q3 | $1.16M | Buy |
33,703
+33,553
| +22,369% | +$1.15M | ﹤0.01% | 2756 |
|
|
2022
Q2 | $2K | Sell |
150
-106,101
| -100% | -$1.41M | ﹤0.01% | 8582 |
|
|
2022
Q1 | $2.42M | Buy |
106,251
+81,921
| +337% | +$1.87M | ﹤0.01% | 2507 |
|
|
2021
Q4 | $897K | Buy |
24,330
+21,030
| +637% | +$775K | ﹤0.01% | 3525 |
|
|
2021
Q3 | $155K | Buy |
3,300
+1,769
| +116% | +$83.1K | ﹤0.01% | 4461 |
|
|
2021
Q2 | $92K | Buy |
+1,531
| New | +$92K | ﹤0.01% | 4915 |
|